Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-008-0034-8
Annals of Surgical Oncology 15:2811-2826 (2008)
© 2008 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wiseman, S. M.
Right arrow Articles by Griffith, O. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wiseman, S. M.
Right arrow Articles by Griffith, O. L.

Original Article

Molecular Phenotyping of Thyroid Tumors Identifies a Marker Panel for Differentiated Thyroid Cancer Diagnosis

Sam M. Wiseman, MD, FRCSC1,2, Adrienne Melck, MD1, Hamid Masoudi, MD1,3, Fariba Ghaidi, MLT1,2, Lynn Goldstein, MD4, Allen Gown, MD3,4, Steven J. M. Jones, PhD5 and Obi L. Griffith, PhD5

1 Department of Surgery, St. Paul’s Hospital, University of British Columbia, C303-1081 Burrard Street, Vancouver, BC, Canada V6Z-1Y6
2 Genetic Pathology Evaluation Center at the Prostate Research Center of Vancouver General Hospital, British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada
3 Department of Pathology, University of British Columbia, Vancouver, BC, Canada
4 PhenoPath Laboratories, Seattle, WA, USA
5 Department of Medical Genetics, British Columbia Cancer Agency, Michael Smith Genome Sciences Center, University of British Columbia, Vancouver, BC, Canada

Correspondence: Address correspondence and reprint requests to: Sam M. Wiseman, MD, FRCSC; E-mail: smwiseman{at}providencehealth.bc.ca

Background: Currently, a large proportion of individuals undergo thyroidectomy as a diagnostic procedure for cancer. The objective of this work was to evaluate the molecular phenotype of differentiated thyroid cancer (DTC) and benign thyroid lesions to identify molecular markers that allow for accurate thyroid cancer diagnosis.

Methods: Tissue microarrays consisting of 100 benign and 105 malignant thyroid lesions, plus 24 lymph node samples, were stained for a panel of 57 molecular markers. Significant associations between marker staining and tumor pathology (DTC versus benign) were determined using contingency table and Mann-Whitney U (MU) tests. A Random Forests classifier algorithm was also used to identify useful/important molecular classifiers.

Results: Of the 57 diagnostic markers evaluated 35 (61%) were significantly associated with a DTC diagnosis after multiple testing correction. Of these, in DTC compared with benign thyroid tumors, 8 markers were downregulated and 27 upregulated. The most significant markers for DTC diagnosis were: Galectin-3, Cytokeratin 19, Vascular Endothelial Growth Factor, Androgen Receptor, p16, Aurora-A, and HBME-1. Using the entire molecular marker panel, a Random Forests algorithm was able to classify tumors as DTC or benign with an estimated sensitivity of 87.9%, specificity of 94.0%, and an accuracy of 91.0%.

Conclusion: Evaluation of the DTC and benign thyroid tumor molecular phenotype has allowed for identification of a marker panel, composed of both established and novel markers, useful for thyroid cancer diagnosis. These results suggest that further study of the molecular profile of thyroid tumors is warranted, and a diagnostic molecular marker panel may potentially improve patient selection for thyroid surgery.

Key Words: Thyroid cancer • Molecular markers • Tissue microarray • Galectin-3






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society of Surgical Oncology.